

Sonia Moretti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9485054/publications.pdf>

Version: 2024-02-01

54
papers

1,622
citations

304743

22
h-index

289244

40
g-index

54
all docs

54
docs citations

54
times ranked

1467
citing authors

#	ARTICLE	IF	CITATIONS
1	Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses. <i>Journal of Immunology</i> , 2002, 168, 197-206.	0.8	158
2	Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. <i>Aids</i> , 1997, 11, 185-190.	2.2	114
3	Effect of <i>Bifidobacterium bifidum</i> and <i>Lactobacillus acidophilus</i> on gut mucosa and peripheral blood B lymphocytes. <i>Immunopharmacology and Immunotoxicology</i> , 1992, 14, 331-340.	2.4	81
4	Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS. <i>Aids</i> , 1994, 8, 655-660.	2.2	81
5	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. <i>Vaccine</i> , 2004, 22, 3258-3269.	3.8	70
6	High Dose L-Carnitine Improves Immunologic and Metabolic Parameters in Aids Patients. <i>Immunopharmacology and Immunotoxicology</i> , 1993, 15, 1-12.	2.4	69
7	Apoptosis and Surgical Trauma. <i>Archives of Surgery</i> , 2000, 135, 1141.	2.2	66
8	L-Carnitine Reduces Lymphocyte Apoptosis and Oxidant Stress in HIV-1-Infected Subjects Treated with Zidovudine and Didanosine. <i>Antioxidants and Redox Signaling</i> , 2002, 4, 391-403.	5.4	65
9	HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection. <i>Journal of Immunology</i> , 2009, 182, 2888-2897.	0.8	65
10	Effect of L-Carnitine on Human Immunodeficiency Virus-1 Infection-Associated Apoptosis: A Pilot Study. <i>Blood</i> , 1998, 91, 3817-3824.	1.4	63
11	Acetyl-L-carnitine Administration Increases Insulin-like Growth Factor 1 Levels in Asymptomatic HIV-1-Infected Subjects: Correlation with Its Suppressive Effect on Lymphocyte Apoptosis and Ceramide Generation. <i>Clinical Immunology</i> , 1999, 92, 103-110.	3.2	61
12	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. <i>PLoS ONE</i> , 2012, 7, e48781.	2.5	56
13	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. <i>Retrovirology</i> , 2015, 12, 33.	2.0	55
14	Apoptosis and apoptosis-associated perturbations of peripheral blood lymphocytes during HIV infection: comparison between AIDS patients and asymptomatic long-term non-progressors. <i>Clinical and Experimental Immunology</i> , 2000, 122, 364-373.	2.6	41
15	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. <i>DNA and Cell Biology</i> , 2002, 21, 599-610.	1.9	35
16	Mitochondrial Perturbations and Oxidant Stress in Lymphocytes From Patients Undergoing Surgery and General Anesthesia. <i>Archives of Surgery</i> , 2001, 136, 1190.	2.2	34
17	HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. <i>Retrovirology</i> , 2016, 13, 34.	2.0	33
18	Modulation of apoptosis and improved redox metabolism with the use of a new antioxidant formula. <i>Biochemical Pharmacology</i> , 2002, 63, 1305-1314.	4.4	32

#	ARTICLE	IF	CITATIONS
19	Problems and emerging approaches in HIV/AIDS vaccine development. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 23-48.	2.4	31
20	Interleukin-10 and Apoptotic Death of Circulating Lymphocytes in Surgical/Anesthesia Trauma. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 51, 92-97.	2.4	25
21	Apoptogenic Effect of Fentanyl on Freshly Isolated Peripheral Blood Lymphocytes. <i>Journal of Trauma</i> , 2004, 57, 75-81.	2.3	23
22	Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. <i>Frontiers in Immunology</i> , 2019, 10, 233.	4.8	23
23	Circulating neutrophils exhibit enhanced apoptosis associated with mitochondrial dysfunctions after surgery under general anaesthesia. <i>Acta Anaesthesiologica Scandinavica</i> , 2001, 45, 87-94.	1.6	22
24	Inosine pranobex in the treatment of HIV infection: A review. <i>International Journal of Immunopharmacology</i> , 1991, 13, 19-27.	1.1	21
25	Oxidative stress and mitochondrial glutathione in human lymphocytes exposed to clinically relevant anesthetic drug concentrations. <i>Journal of Clinical Anesthesia</i> , 2004, 16, 189-194.	1.6	21
26	5-S-Cysteinyldopamine effect on the human dopaminergic neuroblastoma cell line SH-SY5Y. <i>Neurochemistry International</i> , 2006, 49, 262-269.	3.8	21
27	Lymphocyte Apoptosis, Caspase Activation and Inflammatory Response in Septic Shock. <i>Infection</i> , 2008, 36, 485-487.	4.7	21
28	Cell-associated ceramide in HIV-1 -infected subjects. <i>Aids</i> , 1996, 10, 675.	2.2	20
29	A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. <i>Vaccine</i> , 2011, 29, 2918-2932.	3.8	20
30	Ceramide, AIDS and long-term survivors. <i>Trends in Immunology</i> , 1996, 17, 48.	7.5	19
31	Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. <i>Archives of Virology</i> , 2008, 153, 463-472.	2.1	18
32	Containment of Infection in Tat Vaccinated Monkeys After Rechallenge with a Higher Dose of SHIV89.6P _{cy243} . <i>Viral Immunology</i> , 2009, 22, 117-124.	1.3	18
33	Symptomatic Crystalluria Associated with Indinavir. <i>Annals of Pharmacotherapy</i> , 2000, 34, 1414-1418.	1.9	17
34	Advances in SIV/SHIV Non-Human Primate Models of NeuroAIDS. <i>Pathogens</i> , 2021, 10, 1018.	2.8	15
35	Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. <i>Vaccines</i> , 2019, 7, 99.	4.4	14
36	HIV therapeutic vaccines aimed at intensifying HIV combination antiretroviral therapy. <i>Expert Review of Vaccines</i> , 2020, 19, 71-84.	4.4	12

#	ARTICLE	IF	CITATIONS
37	HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. <i>International Journal of Molecular Sciences</i> , 2021, 22, 317.	4.1	12
38	Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.. <i>EBioMedicine</i> , 2021, 66, 103306.	6.1	11
39	In Vivo and in Vitro Efficacy of Fusidic Acid in HIV Infection. <i>Annals of the New York Academy of Sciences</i> , 1993, 685, 341-343.	3.8	9
40	Defective production of interferon- γ and tumour necrosis factor- α by AIDS mononuclear cells after in vitro exposure to <i>Rhodococcus equi</i> . <i>Mediators of Inflammation</i> , 1995, 4, 306-309.	3.0	8
41	Pancuronium bromide, a non-depolarizing muscle relaxant which promotes apoptosis of blood lymphocytes in vitro. <i>Acta Anaesthesiologica Scandinavica</i> , 2003, 47, 1138-1144.	1.6	6
42	New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. <i>Archives of Virology</i> , 2021, 166, 2955-2974.	2.1	6
43	Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy. <i>Pathogens</i> , 2021, 10, 1488.	2.8	5
44	L-carnitine: a partner between immune response and lipid metabolism ?. <i>Mediators of Inflammation</i> , 1993, 2, S29-S32.	3.0	4
45	“cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies” Expert Review of Vaccines, 2017, 17, 1-12.	4.4	4
46	Reduction of Glutamate Levels in HIV-Infected Subjects Treated with Acetylcarnitine. <i>Journal of Neuro-AIDS</i> , 1999, 2, 65-73.	0.2	4
47	Biocompatible Anionic Polymeric Microspheres as Priming Delivery System for Effective HIV/AIDS Tat-Based Vaccines. <i>PLoS ONE</i> , 2014, 9, e111360.	2.5	4
48	Open Randomized Controlled Parallel Study of Ofloxacin versus Trimethoprim-Sulfamethoxazole Treatment of Lower Respiratory Tract and Urinary Infections. <i>Chemotherapy</i> , 1991, 37, 39-48.	1.6	3
49	Combined Antiviral Therapy Reduces Hiv-1 Plasma Load and Improves CD4 Counts But Does Not Interfere with Ongoing Lymphocyte Apoptosis. <i>Immunopharmacology and Immunotoxicology</i> , 1999, 21, 645-665.	2.4	3
50	L-Carnitine, a Modulator of Immunometabolic Homeostasis in Subjects Infected with the Human Immunodeficiency Virus. , 1997, , 215-231.		2
51	EFFECT OF L-CARNITINE TREATMENT IN VIVO ON APOPTOSIS AND CERAMIDE GENERATION IN PERIPHERAL BLOOD LYMPHOCYTES FROM AIDS PATIENTS: CORRELATION WITH IN VITRO RESULTS. <i>Biochemical Society Transactions</i> , 1996, 24, 618S-618S.	3.4	1
52	Synthetic immunomodulators. <i>Cytotechnology</i> , 1991, 5, 11-14.	1.6	0
53	AIDS Patients with Bacterial Lower Respiratory Tract Infections: Treatment with Ofloxacin versus Sulbactam-Ampicillin. <i>Journal of Chemotherapy</i> , 1992, 4, 376-380.	1.5	0
54	Effect of L-Carnitine on Human Immunodeficiency Virus-1 Infection-Associated Apoptosis: A Pilot Study. <i>Blood</i> , 1998, 91, 3817-3824.	1.4	0